MaxCyte
ExPERT STx™ Scalable static or flow electroporation | MaxCyte
The industry’s leading scalable electroporation technology for high-yield, transient expression of complex proteins, vaccines and biologics.
- Rapidly transfect from 75 thousand to 20 billion cells
- High efficiency enables flexible media strategies that can deliver significant cost savings
- Improved yields for decreased development timelines
- Proprietary Flow Electroporation™ Technology
- Faster production of stable clones
- ISO-certified and CE-marked
Supporting Documents
Scientific Brief
MaxCyte® Enabled Innovative SARS-CoV-2 Vaccine Development
You don't want to miss this!
To permanently access these supporting documents, fill out the short form below.
ALREADY ACCESSED THESE DOCUMENTS? SIGN IN
More Scientific Products from MaxCyte
-
JUN 08, 20232023 Lab Compliance Connect -
-
NOV 01, 2023CRISPR Virtual Event Series 2023
- See More
